Vesicular stomatitis virus: A potential therapeutic virus for the treatment of hematologic malignancy

Human Gene Therapy

Volumn 15, Issue 9, 2004, Pages 821-831

  Lichty, Brian D ^a   Stojdl, David F ^a   Taylor, Rebecca A ^a   Miller, Leigh ^a   Frenkel, Irina ^a   Atkins, Harold ^a   Bell, John C ^a,b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B LYMPHOCYTE; CASE REPORT; CELL KILLING; CELL LINE; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; INFECTION SENSITIVITY; LEUKEMIA; MONOCYTE; MULTIPLE MYELOMA; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; T LYMPHOCYTE; VESICULAR STOMATITIS VIRUS;

CELL LINE, TUMOR; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; FLOW CYTOMETRY; HUMANS; LEUKEMIA; LEUKEMIA, LYMPHOCYTIC; LEUKEMIA, MYELOID; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; NEUTROPHILS; PROTEOGLYCANS; SYNDECANS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUSES;

RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

EID: 4544232065     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2004.15.821     Document Type: Article

References (43)

1. ABRAHAM, N., JARAMILLO, M.L., DUNCAN, P.I., METHOT, N., ICELY, P.L., STOJDL, D.F., BARBER, G.N., and BELL, J.C. (1998). The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia. Exp. Cell Res. 244, 394-404.
2. ALAIN, T., HIRASAWA, K., PON, K.J., NISHIKAWA, S.G., URBANSKI, S.J., AUER, Y., LUIDER, J., MARTIN, A., JOHNSTON, R.N., JANOWSKA-WIECZOREK, A., LEE, P.W., and KOSSAKOWSKA, A.E. (2002). Reovirus therapy of lymphoid malignancies. Blood 100, 4146-4153.
3. BELL, J.C., GARSON, K.A., LICHTY, B.D., and STOJDL, D.F. (2002). Oncolytic viruses: programmable tumour hunters. Curr. Gene Ther. 2, 243-254.
4. BERETTA, L., GABBAY, M., BERGER, R., HANASH, S.M., and SONENBERG, N. (1996). Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q- associated leukemias. Oncogene 12, 1593-1596.
5. BOULTWOOD, J., FIDLER, C., LEWIS, S., MACCARTHY, A., SHERIDAN, H., KELLY, S., OSCIER, D., BUCKLE, V.J., and WAINSCOAT, J.S. (1993). Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome. Blood 82, 2611-2616.
6. CHESI, M., KUEHL, W.M., and BERGSAGEL, P.L. (2000). Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann. Oncol. 11(Suppl 1), 131-135.
7. DEISSEROTH, A.B., ZU, Z., CLAXTON, D., HANANIA, E.G., FU, S., ELLERSON, D., GOLDBERG, L., THOMAS, M., JANICEK, K., and ANDERSON, W.F. (1994). Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83, 3068-3076.
8. DIETZSCHOLD, B., RUPPRECHT, C.E., FU, Z.F., and KOPROWSKI, H. (1996). Rhabdoviruses. In Fields Virology. B.N. Fields, D.M. Knipe, and P.M. Howley, eds. (Lippincott-Raven, Philadelphia, PA) pp. 341-346.
9. DUMMER, R., DOBBELING, U., GEERTSEN, R., WILLERS, J., BURG, G., and PAVLOVIC, J. (2001). Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication. Blood 97, 523-527.
10. FIELDS, B.N., and HAWKINS, K. (1967). Human infection with the virus of vesicular stomatitis during an epizootic. N. Engl. J. Med. 277, 989-994.
11. FRANCOEUR, A.M., POLIQUIN, L., and STANNERS, C.P. (1987). The isolation of interferon-inducing mutants of vesicular stomatitis virus with altered viral P function for the inhibition of total protein synthesis. Virology 160, 236-245.
12. GRANDER, D., and EINHORN, S. (1998). Interferon and malignant disease - How does it work and why doesn't it always? Acta Oncol. 37, 331-338.
13. GROTE, D., RUSSELL, S.J., CORNU, T.I., CATTANEO, R., VILE, R., POLAND, G.A., and FIELDING, A.K. (2001). Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97, 3746-3754.
14. HARADA, H., KONDO, T., OGAWA, S., TAMURA, T., KITAGAWA, M., TANAKA, N., LAMPHIER, M.S., HIRAI, H., and TANIGUCHI, T. (1994). Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia: A possible mechanism of tumor suppressor inactivation. Oncogene 9, 3313-3320.
15. HAUS, O. (2000). The genes of interferons and interferon-related factors: localization and relationships with chromosome aberrations in cancer. Arch. Immunol. Ther. Exp. (Warsz) 48, 95-100.
16. HESLOP, H.E., ROONEY, C.M., RILL, D.R., KRANCE, R.A., and BRENNER, M.K. (1996). Use of gene marking in bone marrow transplantation. Cancer Detect. Prev. 20, 108-113.
17. IIDA, S., RAO, P.H., BUTLER, M., CORRADINI, P., BOCCADORO, M., KLEIN, B., CHAGANTI, R.S., and DALLA-FAVERA, R. (1997). Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat. Genet. 17, 226-230.
18. JAHN, G., STENGLEIN, S., RIEGLER, S., EINSELE, H., and SINZGER, C. (1999). Human cytomegalovirus infection of immature dendritic cells and macrophages. Intervirology 42, 365-372.
19. JULKUNEN, I., LINNAVUORI, K., and HOVI, T. (1982). Sensitive interferon assay based on immunoenzymatic quantification of viral antigen synthesis. J. Virol. Methods 5, 85-91.
20. KONDO, T., MINAMINO, N., NAGAMURA-INOUE, T., MATSUMOTO, M., TANIGUCHI, T., and TANAKA, N. (1997). Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 15, 1275-1281.
21. LICHTY, B.D., POWER, A.T., STOJDL, D.F., and BELL, J.C. (2004). Vesicular stomatitis virus: Re-inventing the bullet. Trends Mol. Med. 10, 210-216.
22. LINGE, C., GEWERT, D., ROSSMANN, C., BISHOP, J.A., and CROWE, J.S. (1995). Interferon system defects in human malignant melanoma. Cancer Res. 55, 4099-4104.
23. MARQUARDT, J., HEINZ, H., HEYMER, J., DEEGEN, E., ADOLF, G.R., and LEIBOLD, W. (1992). A method for the assay of "difficult" interferons exemplified with recombinant equine interferon-beta 1. J. Interferon Res. 12, 83-85.
24. MASTERS, P.S., and SAMUEL, C.E. (1983). Mechanism of interferon action: Inhibition of vesicular stomatitis virus replication in human amnion U cells by cloned human leukocyte interferon. I. Effect on early and late stages of the viral multiplication cycle. J. Biol. Chem. 258, 12019-12025.
25. MEDINA, D.J., SHEAY, W., GOODELL, L., KIDD, P., WHITE, E., RABSON, A.B., and STRAIR, R.K. (1999). Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells. Blood 94, 3499-3508.
26. PENG, K.W., AHMANN, G.J., PHAM, L., GREIPP, P.R., CATTANEO, R., and RUSSELL, S.J. (2001). Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98, 2002-2007.
27. PENG, K.W., DONOVAN, K.A., SCHNEIDER, U., CATTANEO, R., LUST, J.A., and RUSSELL, S.J. (2003). Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 101, 2557-2562.
28. PESTKA, S., LANGER, J.A., ZOON, K.C., and SAMUEL, C.E. (1987). Interferons and their actions. Annu. Rev. Biochem. 56, 727-777.
29. RILL, D.R., SANTANA, V.M., ROBERTS, W.M., NILSON, T., BOWMAN, L.C., KRANCE, R.A., HESLOP, H.E., MOEN, R.C., IHLE, J.N., and BRENNER, M.K. (1994). Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84, 380-383.
30. SALONEN, R., and SALMI, A. (1982). An interferon assay based on yield reduction of vesicular stomatitis virus antigen measured by enzyme immunoassay. J. Virol. Methods 5, 143-149.
31. SCHNELL, M.J., BUONOCORE, L., WHITT, M.A., and ROSE, J.K. (1996). The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 70, 2318-2323.
32. STARK, G.R., KERR, I.M., WILLIAMS, B.R., SILVERMAN, R.H., and SCHREIBER, R.D. (1998). How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264.
33. STOJDL, D.F., LICHTY, B., KNOWLES, S., MARIUS, R., ATKINS, H., SONENBERG, N., and BELL, J.C. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825.
34. STOJDL, D.F., LICHTY, B.D., TENOEVER, B.R., PATERSON, J.M., POWER, A.T., KNOWLES, S., MARIUS, R., REYNARD, J., POLIQUIN, L., ATKINS, H., BROWN, E.G., DURBIN, R.K., DURBIN, J.E., HISCOTT, J., and BELL, J.C. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263-275.
35. STRAIR, R.K., SHEAY, W., GOODELL, L., WHITE, E., RABSON, A.B., and MEDINA, D.J. (2002). Adenovirus infection of primary malignant lymphoid cells. Leuk. Lymphoma 43, 37-49.
36. TANAKA, N., and TANIGUCHI, T. (2000). The interferon regulatory factors and oncogenesis. Semin. Cancer Biol. 10, 73-81.
37. THIRUKKUMARAN, C.M., LUIDER, J.M., STEWART, D.A., CHENG, T., LUPICHUK, S.M., NODWELL, M.J., RUSSELL, J.A., AUER, I.A., and MORRIS, D.G. (2003). Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 102, 377-387.
38. TSUBOI, K., IIDA, S., INAGAKI, H., KATO, M., HAYAMI, Y., HANAMURA, I., MIURA, K., HARADA, S., KIKUCHI, M., KOMATSU, H., BANNO, S., WAKITA, A., NAKAMURA, S., EIMOTO, T., and UEDA, R. (2000). MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 14, 449-456.
39. TZOANOPOULOS, D., SPELETAS, M., ARVANITIDIS, K., VEIOPOULOU, C., KYRIAKI, S., THYPHRONITIS, G., SIDERAS, P., KARTALIS, G., and RITIS, K. (2002). Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia. Br. J. Haematol. 119, 46-53.
40. VAN DEN BERGHE, H., VERMAELEN, K., MECUCCI, C., BARBIERI, D., and TRICOT, G. (1985). The 5q-anomaly. Cancer Genet. Cytogenet. 17, 189-255.
41. WILLMAN, C.L., SEVER, C.E., PALLAVICINI, M.G., HARADA, H., TANAKA, N., SLOVAK, M.L., YAMAMOTO, H., HARADA, K., MEEKER, T.C., LIST, A.F., et al. (1993). Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259, 968-971.
42. YAMADA, M., ASANUMA, K., KOBAYASHI, D., MORIAI, R., YAJIMA, T., YAGIHASHI, A., YAMAMORI, S., and WATANABE, N. (2001). Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes. Anticancer Res. 21, 633-638.
43. YOSHIDA, S., NAKAZAWA, N., IIDA, S., HAYAMI, Y., SATO, S., WAKITA, A., SHIMIZU, S., TANIWAKI, M., and UEDA, R. (1999). Detection of MUM1/IRF4-IgH fusion in multiple myeloma. Leukemia 13, 1812-1816.